Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014650 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers
A Phase 1 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01014650 is a Phase 1 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 53 participants.
The verdict
NCT01014650, a Phase 1 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional partial agonist, in normal, healthy human volunteers.
Interventions
- DRUG IV normal saline
- DRUG GLYX-13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014650
The ClinicalTrials.gov registry entry for NCT01014650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV normal saline is the first listed.
NCT01014650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014650 about?
NCT01014650 is a clinical study titled "Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional partial agonist, in normal, healthy human volunteers.
What is the current status of trial NCT01014650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2009-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01014650?
The interventions under investigation include: IV normal saline (DRUG), GLYX-13 (DRUG).
Who is sponsoring clinical trial NCT01014650?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.